These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 30529691

  • 1. The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo.
    Gilson P, Couvet M, Vanwonterghem L, Henry M, Vollaire J, Baulin V, Werner M, Orlowska A, Josserand V, Mahuteau-Betzer F, Lafanechère L, Coll JL, Busser B, Hurbin A.
    Biochem Pharmacol; 2019 Feb; 160():1-13. PubMed ID: 30529691
    [Abstract] [Full Text] [Related]

  • 2. Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.
    Gilson P, Josa-Prado F, Beauvineau C, Naud-Martin D, Vanwonterghem L, Mahuteau-Betzer F, Moreno A, Falson P, Lafanechère L, Frachet V, Coll JL, Fernando Díaz J, Hurbin A, Busser B.
    Sci Rep; 2017 Aug 31; 7(1):10209. PubMed ID: 28860487
    [Abstract] [Full Text] [Related]

  • 3. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
    Gunasekaran VP, Nishi K, Sivakumar D, Sivaraman T, Mathan G.
    Eur J Pharm Sci; 2018 Apr 30; 116():2-14. PubMed ID: 28916481
    [Abstract] [Full Text] [Related]

  • 4. Novel water-soluble substituted pyrrolo[3,2-d]pyrimidines: design, synthesis, and biological evaluation as antitubulin antitumor agents.
    Gangjee A, Pavana RK, Li W, Hamel E, Westbrook C, Mooberry SL.
    Pharm Res; 2012 Nov 30; 29(11):3033-9. PubMed ID: 22814902
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.
    Rickardson L, Kutvonen E, Orasniemi S, Högberg M, Kallio MJ, Rehnmark S.
    Drug Des Devel Ther; 2017 Nov 30; 11():1335-1351. PubMed ID: 28496304
    [Abstract] [Full Text] [Related]

  • 6. Pivalopril improves anti-cancer efficiency of cDDP in breast cancer through inhibiting proliferation, angiogenesis and metastasis.
    Fei L, Huimei H, Dongmin C.
    Biochem Biophys Res Commun; 2020 Dec 17; 533(4):853-860. PubMed ID: 33008601
    [Abstract] [Full Text] [Related]

  • 7. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
    Canela MD, Noppen S, Bueno O, Prota AE, Bargsten K, Sáez-Calvo G, Jimeno ML, Benkheil M, Ribatti D, Velázquez S, Camarasa MJ, Díaz JF, Steinmetz MO, Priego EM, Pérez-Pérez MJ, Liekens S.
    Oncotarget; 2017 Feb 28; 8(9):14325-14342. PubMed ID: 27224920
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q, Wang Y, Wang R, Lai W, Tang L, Tao Y, Liu Y, Zhang R, Huang L, Xiang H, Zeng S, Gou L, Chen H, Yao Y, Yang J.
    Eur J Med Chem; 2018 Aug 05; 156():162-179. PubMed ID: 30006162
    [Abstract] [Full Text] [Related]

  • 9. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L, Wang Y, Du H, Jiang Y, Tang Z, Liu H, Xiang H, Xiao H.
    Cancer Chemother Pharmacol; 2015 Dec 05; 76(6):1247-57. PubMed ID: 26464351
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Wang J, Lu Z, Wu C, Li Y, Kong Y, Zhou R, Shi K, Guo J, Li N, Liu J, Song W, Wang H, Zhu M, Xu H.
    Prostate; 2019 Jan 05; 79(1):62-72. PubMed ID: 30242862
    [Abstract] [Full Text] [Related]

  • 11. Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine.
    Mohan L, Raghav D, Ashraf SM, Sebastian J, Rathinasamy K.
    Biomed Pharmacother; 2018 Sep 05; 105():506-517. PubMed ID: 29883946
    [Abstract] [Full Text] [Related]

  • 12. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W.
    Int J Oncol; 2012 May 05; 40(5):1501-14. PubMed ID: 22200632
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
    Wang F, Yang Z, Liu Y, Ma L, Wu Y, He L, Shao M, Yu K, Wu W, Pu Y, Nie C, Chen L.
    Bioorg Med Chem; 2015 Jul 01; 23(13):3337-50. PubMed ID: 25937236
    [Abstract] [Full Text] [Related]

  • 14. Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Oluwalana D, Adeleye KL, Krutilina RI, Chen H, Playa H, Deng S, Parke DN, Abernathy J, Middleton L, Cullom A, Thalluri B, Ma D, Meibohm B, Miller DD, Seagroves TN, Li W.
    Cancer Lett; 2024 Aug 10; 597():217011. PubMed ID: 38849011
    [Abstract] [Full Text] [Related]

  • 15. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.
    Liu YN, Wang JJ, Ji YT, Zhao GD, Tang LQ, Zhang CM, Guo XL, Liu ZP.
    J Med Chem; 2016 Jun 09; 59(11):5341-55. PubMed ID: 27172319
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
    Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, Jarman EJ, Renshaw L, Um IH, Kay C, Harrison DJ, Kunkler IH, Langdon SP.
    Oncotarget; 2015 Sep 22; 6(28):24856-70. PubMed ID: 26259239
    [Abstract] [Full Text] [Related]

  • 17. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, Ryan AJ, Giavazzi R.
    Clin Cancer Res; 2005 Apr 01; 11(7):2720-6. PubMed ID: 15814654
    [Abstract] [Full Text] [Related]

  • 18. Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis.
    Sinha S, Khan S, Shukla S, Lakra AD, Kumar S, Das G, Maurya R, Meeran SM.
    Int J Biochem Cell Biol; 2016 Aug 01; 77(Pt A):41-56. PubMed ID: 27210504
    [Abstract] [Full Text] [Related]

  • 19. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
    Magalhaes LG, Marques FB, da Fonseca MB, Rogério KR, Graebin CS, Andricopulo AD.
    PLoS One; 2016 Aug 01; 11(8):e0160842. PubMed ID: 27508497
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
    Kilic-Kurt Z, Bakar-Ates F, Karakas B, Kütük Ö.
    Anticancer Agents Med Chem; 2018 Aug 01; 18(9):1303-1312. PubMed ID: 29866023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.